Status:
RECRUITING
Human Amniotic Mesenchymal Cell Secretome for Neurodegeneration and Neuroinflammation
Lead Sponsor:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Conditions:
Amyotrophic Lateral Sclerosis
Multiple Sclerosis
Eligibility:
All Genders
20-60 years
Phase:
NA
Brief Summary
Neurodegenerative diseases are debilitating conditions characterized by chronic inflammation, leading to dysfunction of both the non-neuronal cellular components of the central nervous system and peri...
Eligibility Criteria
Inclusion
- For patients with amyotrophic lateral sclerosis (ALS): aged between 50 and 60 years and similar age of onset and duration of the disease.
- For patients with multiple sclerosis (MS): with recently confirmed diagnosis of MS, aged between 20 and 50 years and considering the male-to-female ratio in MS of approximately 2:1.
- For healthy volunteers: spouses of patients unaffected by any neurological disease and matching their age and gender ratio for both conditions.
Exclusion
- Patients who do not consent to participate in the study.
- MS patients who have received treatment with immunomodulators or corticosteroids and are in an acute phase of the disease.
Key Trial Info
Start Date :
January 17 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 30 2026
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06551649
Start Date
January 17 2025
End Date
September 30 2026
Last Update
August 14 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Fondazione Policlinico Universitario A. Gemelli IRCCS
Roma, Italy, 00168
2
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Rome, Italy, 00168